阿奇黴素二水合物市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

全球二水合氨黴素市場預計將從 2025 年的 4,710 噸成長到 2031 年的 6,640 噸，複合年成長率為 5.89%。

作為一種頻譜大環內酯類抗生素，阿奇黴素廣泛用於治療輕度至中度細菌感染疾病，特別適用於皮膚、軟組織和呼吸系統感染。市場成長的主要驅動力是全球性行為感染感染疾病和社區型肺炎發病率的上升，這些疾病需要價格合理且容易取得的治療方案。此外，該藥物優異的藥物動力學特性，使其能夠每日一次給藥並縮短療程，從而提高患者依從性，並維持成人和兒童患者群體的強勁需求。例如，美國疾病管制與預防中心 (CDC) 報告稱，2024 年美國將開出約 3,630 萬張阿奇黴素處方箋。

儘管市場需求穩定，但日益嚴重的抗生素抗藥性給市場帶來了巨大挑戰，對長期發展構成威脅。大環內酯類抗生素的濫用加劇了抗藥性菌株的擴散，迫使醫療機構轉向其他抗生素，從而有效縮小了阿奇黴素產品的市場規模。抗藥性細菌帶來的壓力，加上旨在限制不必要抗生素使用的監管舉措，共同構成了全球阿奇黴素二水合物產業持續成長的障礙。

市場促進因素

細菌性呼吸道感染疾病的日益增多是全球阿奇黴素二水合物市場的主要促進因素，推動了這種廣譜頻譜的持續銷售量成長。肺炎鏈球菌和黴漿菌等病原體是社區流行性肺炎的常見原因，而阿奇黴素起效迅速、通訊協定短，因此在臨床實踐中仍被廣泛依賴。這種高需求量往往超過產能，導致間歇性供不應求，凸顯了該藥物的重要性。根據美國食品藥物管理局（FDA）2025年9月發布的公告，某些阿奇黴素製劑已被列入FDA的藥品短缺資料庫，顯示由於呼吸道治療的持續需求，該藥物存在嚴重的供應短缺。

同時，需要使用抗生素治療的性行為感染（STI）病例的增加顯著推高了市場需求，尤其是淋病和披衣菌感染的治療方法。阿奇黴素的單劑量特性顯著提高了患者在性健康護理中的用藥依從性，鞏固了其在開發中國家和已開發國家作為標準治療藥物的地位。根據美國疾病管制與預防中心（CDC）於2025年9月發布的《2024年性行為感染監測報告》，2024年美國報告的性行為感染病例超過220萬例，處方率居高不下。英國衛生安全局（UKHSA）在其2025年6月發布的報告《UKHSA發布最新性行為感染數據》中進一步凸顯了這一問題的全球性嚴重性，報告指出，2024年英格蘭的淋病診斷病例數達到71,802例，證實了抗生素治療的廣泛需求。

市場挑戰

抗生素抗藥性的日益嚴重限制了全球阿奇黴素二水合物市場的成長，因為它降低了藥物的臨床療效，迫使人們轉向其他療法。隨著細菌病原體對大環內酯類抗生素的敏感性降低，衛生部門被迫更新標準治療通訊協定，這往往導致阿奇黴素不再是治療感染疾病和性行為感染感染等常見疾病的第一線藥物。這種臨床和監管重點的轉變直接減少了阿奇黴素的處方量，並縮小了其目標患者群體，因為醫療專業人員會選擇其他類別的抗生素以確保可靠的治療效果。

近期監測數據顯示抗藥性菌株迅速傳播，印證了這一趨勢的影響。世界衛生組織（WHO）預測，到2025年，淋病奈瑟菌分離株對阿奇黴素的抗藥性率將從2022年的0.5%上升至2024年的4%。這項療效降低的統計證據支持合理使用抗菌藥物的概念，即限制大環內酯類抗生素的使用，以減緩抗藥性的進一步發展。因此，療效降低和更嚴格的處方指南共同構成了全球阿奇黴素二水合物市場銷售成長的持續障礙。

市場趨勢

隨著製藥公司積極減少對單一來源關鍵抗生素前驅物的依賴，全球原料藥（API）供應鏈的策略多元化正在重塑市場格局。這一趨勢的特點是，尤其是在印度，生產獎勵顯著轉向區域性，以抵消地緣政治風險並確保關鍵大環內酯類藥物的供應安全。各國政府正在建立強而有力的金融框架，以促進關鍵起始原料（KSM）的國內生產，這些原料過去主要依賴從中國進口。根據2025年5月《eHealth》雜誌題為「政府徵集生產關聯激勵計劃（PLI）下的新申請以促進國內原料藥生產」的報道，印度藥品管理局已向國內生產商分配了總合1600噸的硫氰酸紅黴素（阿奇黴素合成的關鍵前體）產能，以降低進口依賴。

同時，隨著產業領導者將環境責任置於優先地位，以應對源自工業廢棄物的抗生素抗藥性細菌的蔓延，永續綠色化學製造的採用正在加速。製造商正積極利用酵素法製程和先進的廢棄物管理系統，以減少抗生素殘留物流入水道，並滿足日益嚴格的國際環境標準。這種營運模式的轉變不僅解決了生態系統問題，還透過減少合成和發酵過程中的公用設施消耗和碳足跡，提高了效率。根據Centrient Pharmaceuticals於2025年6月發布的《2024年ESG報告》，該公司已成功將其範圍1和範圍2的溫室氣體排放在2024年較2022年的基準值降低了8%，這充分體現了該行業對永續生產方式的切實承諾。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球阿奇黴素二水合物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 產品細分（原料藥級阿奇黴素二水合物、藥用級阿奇黴素二水合物、科研級阿奇黴素二水合物）
  • 依用途（抗生素、呼吸道感染疾病、性行為感染感染、皮膚感染疾病）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美阿奇黴素二水合物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲阿奇黴素二水合物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區二水合阿奇黴素市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲阿奇黴素二水合物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美阿奇黴素二水合物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球二水合阿奇黴素市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan NV

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Azithromycin Dihydrate Market is projected to expand from 4.71 Thousand Tonnes in 2025 to 6.64 Thousand Tonnes by 2031, registering a compound annual growth rate of 5.89%. Functioning as a broad-spectrum macrolide antibiotic, this pharmaceutical is extensively prescribed for mild to moderate bacterial infections, specifically those impacting the skin, soft tissues, and respiratory tract. The market's trajectory is primarily propelled by the growing worldwide incidence of sexually transmitted infections and community-acquired pneumonia, which demand affordable and accessible therapeutic solutions. Additionally, the drug's advantageous pharmacokinetic profile-enabling once-daily dosing and shorter treatment durations-bolsters patient adherence and maintains robust demand across adult and pediatric populations. Highlighting this dominance, the Centers for Disease Control and Prevention reported that in 2024, approximately 36.3 million outpatient prescriptions for azithromycin were dispensed in the United States.

Despite this steady demand, the market encounters significant obstacles stemming from increasing antimicrobial resistance, which poses a threat to long-term development. The spread of resistant bacterial strains, aggravated by the overuse of macrolides, necessitates that healthcare providers transition toward alternative antibiotic classes, effectively shrinking the accessible market for azithromycin products. This pressure from resistance, coupled with regulatory stewardship initiatives designed to limit unnecessary antibiotic intake, creates an enduring impediment to the sustained volumetric expansion of the global azithromycin dihydrate industry.

Market Driver

The rising prevalence of bacterial respiratory tract infections acts as the central engine for the Global Azithromycin Dihydrate Market, fueling continuous volume growth for this broad-spectrum macrolide. Because pathogens like Streptococcus pneumoniae and Mycoplasma pneumoniae are frequent causes of widespread community-acquired pneumonia, clinical dependence on azithromycin persists due to its rapid effectiveness and brief treatment protocols. This elevated consumption often exceeds production capacities, resulting in intermittent availability issues that highlight the drug's critical nature. According to the U.S. Food and Drug Administration in September 2025, specific azithromycin formulations were listed in the agency's drug shortage database, signaling the intense supply strain driven by these enduring respiratory treatment requirements.

Simultaneously, the growing burden of sexually transmitted infections (STIs) requiring antibiotic intervention significantly reinforces market demand, especially for gonorrhea and chlamydia treatment regimens. Azithromycin's single-dose capability provides a vital benefit for patient compliance within sexual health initiatives, cementing its role as a standard therapy in both developing and developed nations. According to the Centers for Disease Control and Prevention's 'Sexually Transmitted Infections Surveillance, 2024' report released in September 2025, over 2.2 million reportable STI cases were recorded in the United States in 2024, maintaining high prescription rates. Underscoring the global scale of this issue, the UK Health Security Agency noted in its 'UKHSA publishes latest STI data' from June 2025 that gonorrhoea diagnoses in England reached 71,802 in 2024, confirming the extensive need for antibiotic intervention.

Market Challenge

The rise of antimicrobial resistance presents a formidable constraint to the growth of the Global Azithromycin Dihydrate Market by diminishing the drug's clinical effectiveness and forcing a transition to alternative treatments. As bacterial pathogens exhibit lower susceptibility to macrolides, health authorities are increasingly obligated to update standard treatment protocols, frequently removing azithromycin from its position as a first-line therapy for prevalent conditions like respiratory tract infections and sexually transmitted infections. This shift in clinical and regulatory focus directly reduces prescription quantities, as practitioners select other antibiotic classes to guarantee successful outcomes, thereby narrowing the addressable patient population for azithromycin formulations.

Recent surveillance data underscoring the swift spread of resistant strains substantiates the impact of this trend. According to the World Health Organization in 2025, resistance to azithromycin within Neisseria gonorrhoeae isolates increased globally from 0.5% in 2022 to 4% in 2024. Such statistical proof of reduced efficacy supports antibiotic stewardship programs that limit macrolide use to postpone further resistance development. Consequently, the convergence of declining therapeutic efficacy and stricter prescribing guidelines forms a lasting obstacle to the volume growth of the global azithromycin dihydrate sector.

Market Trends

The strategic diversification of global API supply chains is transforming the market as pharmaceutical firms actively decrease their reliance on single-source producers for essential antibiotic precursors. This movement is defined by a notable pivot toward localized manufacturing incentives, especially within India, to offset geopolitical risks and guarantee the security of critical macrolide supplies. Governments are establishing strong financial structures to promote the domestic production of Key Starting Materials (KSMs) that were previously imported primarily from China. According to eHealth Magazine's May 2025 report, 'Govt Invites Fresh Applications Under PLI Scheme to Boost Domestic Bulk Drug Production,' the Indian Department of Pharmaceuticals assigned a combined production capacity of 1,600 metric tons for Erythromycin Thiocyanate, the main precursor for azithromycin synthesis, to domestic manufacturers to limit import dependence.

Concurrently, the adoption of sustainable green chemistry manufacturing is gathering momentum as industry leaders prioritize environmental responsibility to fight the dissemination of antimicrobial resistance caused by industrial waste. Manufacturers are increasingly utilizing enzymatic methods and advanced waste management systems to limit the release of antibiotic residues into waterways, complying with stricter global environmental standards. This operational shift not only tackles ecological issues but also improves efficiency by lowering utility usage and carbon footprints during synthesis and fermentation. According to Centrient Pharmaceuticals' 'ESG Report 2024' released in June 2025, the company achieved an 8% reduction in its Scope 1 and 2 greenhouse gas emissions in 2024 against its 2022 baseline, demonstrating the sector's concrete dedication to sustainable production methods.

Key Market Players

• Pfizer Inc
• Teva Pharmaceutical Industries Ltd.
• Sandoz International GmbH
• Arbindo Pharma Limited
• Mylan N.V

Report Scope

In this report, the Global Azithromycin Dihydrate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Azithromycin Dihydrate Market, By Product

• API Grade Azithromycin Dihydrate
• Pharmaceutical Grade Azithromycin Dihydrate
• Research Grade Azithromycin Dihydrate

Azithromycin Dihydrate Market, By Application

• Antibiotics
• Respiratory Infections
• Sexually Transmitted Diseases
• Skin Infections

Azithromycin Dihydrate Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Azithromycin Dihydrate Market.

Available Customizations:

Global Azithromycin Dihydrate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Azithromycin Dihydrate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (API Grade Azithromycin Dihydrate, Pharmaceutical Grade Azithromycin Dihydrate, Research Grade Azithromycin Dihydrate)
  • 5.2.2. By Application (Antibiotics, Respiratory Infections, Sexually Transmitted Diseases, Skin Infections)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Azithromycin Dihydrate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Azithromycin Dihydrate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Azithromycin Dihydrate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Azithromycin Dihydrate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Azithromycin Dihydrate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Azithromycin Dihydrate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. France Azithromycin Dihydrate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Azithromycin Dihydrate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Azithromycin Dihydrate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Azithromycin Dihydrate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Azithromycin Dihydrate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Azithromycin Dihydrate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Azithromycin Dihydrate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Azithromycin Dihydrate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Azithromycin Dihydrate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Azithromycin Dihydrate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. Middle East & Africa Azithromycin Dihydrate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Azithromycin Dihydrate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Azithromycin Dihydrate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Azithromycin Dihydrate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. South America Azithromycin Dihydrate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Azithromycin Dihydrate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Azithromycin Dihydrate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Azithromycin Dihydrate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Azithromycin Dihydrate Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sandoz International GmbH
• 15.4. Arbindo Pharma Limited
• 15.5. Mylan N.V

16. Strategic Recommendations

17. About Us & Disclaimer